KalVista Pharmaceuticals, Inc. (KALV)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

KalVista Pharmaceuticals, Inc. (KALV) is up 66.9% since the beginning of the year. At $27 per share, KALV is currently trading at its 52-week high. Investors who bought $1,000 worth of KALV shares 5 years ago would now be looking at an investment worth $1,020.

KalVista Pharmaceuticals, Inc. (KALV) has returned 66.87% so far this year and 101.87% over the past 12 months. Over the last ten years, KALV has returned 3.38% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Apr 9, 2015, KALV's average daily return is +0.11%, while the average monthly return is +2.17%. At this rate, an investment would double in approximately 2.7 years.

Historically, 47% of months were positive and 53% were negative. The best month was Feb 2021 with a return of +116.3%, while the worst month was Feb 2016 at -74.5%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.

On a daily basis, KALV closed higher 48% of trading days. The best single day was Feb 9, 2021 with a return of +114.6%, while the worst single day was Feb 2, 2016 at -73.3%.

KalVista Pharmaceuticals, Inc. has an annualized alpha of 16.00%, beta of 0.95, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since April 10, 2015.

• This stock participated in 171.26% of S&P 500 Index downside but only 84.18% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

KALV ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for KalVista Pharmaceuticals, Inc. (KALV) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the KalVista Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the KalVista Pharmaceuticals, Inc. was 96.68%, occurring on Oct 19, 2022. The portfolio has not yet recovered.

The current KalVista Pharmaceuticals, Inc. drawdown is 78.71%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of KalVista Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how KalVista Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.